Edition:
India

Cellect Biotechnology Ltd (APOP.OQ)

APOP.OQ on NASDAQ Stock Exchange Capital Market

0.52USD
1:30am IST
Change (% chg)

$0.03 (+5.18%)
Prev Close
$0.49
Open
$0.52
Day's High
$0.52
Day's Low
$0.49
Volume
4,495
Avg. Vol
32,996
52-wk High
$7.39
52-wk Low
$0.47

Latest Key Developments (Source: Significant Developments)

Cellect Biotechnology To Reduce Workforce By Approximately 40%
Friday, 7 Jun 2019 

June 6 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY LTD - ON JUNE 2, BOARD APPROVED A COST REDUCTION PROGRAM - SEC FILING.CELLECT BIOTECHNOLOGY LTD - COST REDUCTION PROGRAM INCLUDES REDUCTION OF WORKFORCE BY APPROXIMATELY 40%.CELLECT BIOTECHNOLOGY - COST REDUCTION PROGRAM ALSO INCLUDES SALARY REDUCTIONS FOR REMAINING EMPLOYEES.CELLECT BIOTECHNOLOGY -COST REDUCTION PROGRAM ALSO INCLUDES GRANT TO CHAIRMAN, CEO, CFO & OTHER EMPLOYEES OF OPTIONS TO PURCHASE 650,000 OF CO'S ADS.CELLECT BIOTECHNOLOGY - CO ENTERED INTO CONSULTING AGREEMENT WITH FINANCIAL ADVISOR TO ADVISE CO IN CONNECTION WITH CONSIDERATION OF STRATEGIC ALTERNATIVES.  Full Article

Cellect Biotechnology Qtrly Net Loss $0.008 Per Share And $0.16 Per ADS
Tuesday, 21 May 2019 

May 21 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY REPORTS FIRST QUARTER 2019 FINANCIAL AND OPERATING RESULTS.CELLECT BIOTECHNOLOGY LTD QTRLY NET LOSS $0.008 PER SHARE AND $0.16 PER ADS.CELLECT BIOTECHNOLOGY LTD - COMPANY'S CASH AND CASH EQUIVALENTS TOTALED $9.6 MILLION AS OF MARCH 31, 2019.  Full Article

Cellect Biotechnology Ltd QTRLY Total Comprehensive Loss Per Share $0.008
Tuesday, 19 Mar 2019 

Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS AND RECENT CORPORATE PROGRESS.CELLECT BIOTECHNOLOGY LTD QTRLY TOTAL COMPREHENSIVE LOSS PER SHARE $0.008.  Full Article

Cellect Biotechnology Determined To Withdraw Sole Proposal To Elect External Director At Co's Extraordinary Meeting Of Shareholders
Thursday, 6 Sep 2018 

Sept 5 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY - DETERMINED TO WITHDRAW SOLE PROPOSAL TO ELECT EXTERNAL DIRECTOR AT CO'S EXTRAORDINARY MEETING OF SHAREHOLDERS.CELLECT BIOTECHNOLOGY - DETERMINED TO WITHDRAW PROPOSAL DUE TO CONFLICT OF INTEREST DISQUALIFIED CANDIDATE FROM SERVING AS EXTERNAL DIRECTOR.CELLECT BIOTECHNOLOGY - INTENDS TO PROPOSE NEW CANDIDATE FOR ELECTION AS AN EXTERNAL DIRECTOR, TO CONVENE A SHAREHOLDERS’ MEETING.  Full Article

Cellect Biotechnology Net Loss For Q2 $0.013 Per Share
Friday, 10 Aug 2018 

Aug 9 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD - NET LOSS FOR Q2 WAS $0.013 PER SHARE & $0.25 PER ADS.  Full Article

Cellect Biotechnology Granted Key European Patent For Its Stem Cell Selection Technology
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY GRANTED KEY EUROPEAN PATENT FOR ITS STEM CELL SELECTION TECHNOLOGY.  Full Article

Cellect Biotechnology Q4 Loss Per Share ‍$0.008​
Tuesday, 20 Mar 2018 

March 19 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD - QTRLY LOSS PER SHARE ‍$0.008​.CELLECT BIOTECHNOLOGY - ‍CASH AND CASH EQUIVALENTS TOTALED $8.0 MILLION AS OF DEC 31, 2017, COMPARED TO $9.4 MILLION ON SEPT 30, 2017​.  Full Article

Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Cellect Biotechnology Ltd ::CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION.CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO'S ONGOING PHASE I/II STUDY​.CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​.  Full Article

Cellect Biotechnology reports Q3 ‍loss $0.02/shr​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology Ltd provides corporate update and reports third quarter 2017 financial results.Cellect Biotechnology Ltd - qtrly ‍loss per share $0.02​.  Full Article

Cellect Biotechnology announces $4.3 million raise in a registered direct offering
Thursday, 7 Sep 2017 

Sept 7 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology announces $4.3 million raise in a registered direct offering.Cellect Biotechnology Ltd - ‍entered into securities purchase agreements with certain accredited investors to receive gross proceeds of $4.3 million​.Cellect Biotechnology Ltd -in connection with offering, co will issue 531,136 adss at a purchase price of $8.10 per ads.  Full Article

No consensus analysis data available.